Cargando…

OA03.08. Clinical study of shaliparni ksheer paka in the management of hypertension

PURPOSE: Hypertension is reported as the third ranked factor for disability adjusted life years and is one of the primary risk factors for heart diseases and stroke, the leading cause of death worldwide. Overall, approximately 20% of world's adults are estimated to have hypertension. However, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Preeti, Sevatkar, Balakrishna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2013
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4147501/
http://dx.doi.org/10.4103/0257-7941.123845
Descripción
Sumario:PURPOSE: Hypertension is reported as the third ranked factor for disability adjusted life years and is one of the primary risk factors for heart diseases and stroke, the leading cause of death worldwide. Overall, approximately 20% of world's adults are estimated to have hypertension. However, there is no definite term given in Ayurveda which clearly represents the disease but many scholars have tried to suggest some appropriate names to hypertension on the basis of their research and pathogenesis of the disease like Dhamani paripurnata, Uccharaktachapa, Siragata vata, Raktagata vata, Avritta vata roga, Rakta sampeedana etc. For its treatment, use of lifelong administration of antihypertensive drugs leads to many side effects. Hence, the present study has been under taken with the hope of searching out a better, safer, low economic remedy for the disease by evaluating the therapeutic effects of Shaliparni ksheer Paka and comparing it with the effects of allopathic drug Tab. ‘Telmisartan’ in the management of hypertension. METHOD: Clinical study was carried out on 60 patients of hypertension, selected randomly from OPD/IPD of Arogyashala, N.I.A., Jaipur which were categorized into two groups. 30 Patients of Group A were treated with control drug Telmisartan – 20mg or 40 mg, OD and 30 patients of Group B were treated with Trial drug Shaliparni Ksheer Paka, (Ch. Chi. 28/9), 150 ml, twice a day for 45 days. Results before treatment and after treatment was compared and analyzed statistically. RESULT: The study reveals that Patients in Group A showed more improvement in reducing the blood pressure whereas that of Group B showed more improvement on the symptoms produced in hypertension and the cholesterol level which was statistically significant. CONCLUSION: The drug Shaliparni Ksheer Paka can be used efficiently in the management of hypertension.